USFDA inspection at Hyderabad facility ends with Form 483 carrying 5 observations

Regulatory & Legal View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹428.40

prior close

₹417.90

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+1.6% vs market

Pharmaceuticals peers, median of 167sector-0.2%+2.0% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Smallcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.1

15m

+2.9

30m

+6.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8+0.2+1.6-0.2+2.0

Next day

+4.2+0.2+4.0+0.3+3.9

+4.5+0.1+4.4+0.6+3.9

+8.4+0.3+8.0+0.6+7.7

+3.8+0.1+3.7+0.5+3.3

+3.6+0.2+3.4+0.9+2.8

+4.3-0.1+4.4-0.2+4.6

15d

+5.9+0.6+5.3-0.2+6.1

+5.5+0.9+4.6+2.3+3.2

+6.7-2.3+9.0+2.4+4.3

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences' Pashamylaram, Hyderabad manufacturing unit was inspected by the USFDA from July 27 to August 5, 2026. The inspection ended with a Form 483 carrying five observations. The company confirmed none relate to data integrity. Cohance is preparing a response with corrective and preventive actions (CAPAs) for submission within the required timeline. Management says the observations are addressable and it will work closely with the USFDA. No warning letter or import alert has been mentioned.

Likely market impact

Form 483 with 5 observations is manageable in principle. Watch for any escalation to a warning letter or import alert, which would impact US business.